Recent clinical trials have demonstrated a statistically significant increase of both progression-free survival (PFS) and overall survival (OS) in BRAF V600 melanoma patients treated with BRAF and MEK inhibitors [5]. The gene discussed is MAP2K7; the disease is melanoma.